Table 2.
Baseline studies’ characteristics
| Age | Male | BMI | HTN | DM | CABG | VD | Aorta | PE grade 1 | PE grade 2 | PE grade 3 | PE grade 4 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amoli et al. (2015) | Placebo | 59.3 ± 10.2 | 44 (59.5%) | 27.2 ± 4.3 | 29 (39.2%) | 26 (35.1%) | 49 (66.2%) | 8 (10.8%) | 14 (18.9%) | 20 (27%) | 18 (24.3%) | 4 (5.4%) | |
| Colchicine | 55.3 ± 11.2 | 45 (60.0%) | 26.5 ± 4.8 | 37 (49.3%) | 19 (25.3%) | 50 (66.7%) | 15 (20%) | 9 (12%) | 35 (46.7%) | 10 (13.3%) | 5 (6.7%) | ||
| Bunge et al. (2014) | Placebo | 64.7 ± 12.7 | 250 (62.3%) | 192 (47.9%) | 53 (13.1%) | 140 (33%) | 281 (66.7%) | ||||||
| Dexamethasone | 65.5 ± 13.1 | 268 (63.7%) | 211 (50.1%) | 60 (14.3%) | 117 (29%) | 284 (70.8%) | |||||||
| Finkelstein et al. (2002) | Placebo | 65 ± 10 | 45 (40.5%) | 48 (43,8%) | 29 (26,6%) | 52 (46.8%) | 10 (-9%) | ||||||
| Colchicine | 62 ± 12 | 36 (32.4%) | 54 (48,9%) | 31 (27,7%) | 38 (-34%) | 6 (5.4%) | |||||||
| Imazio et al. (2010) | Placebo | 67 ± 11 | 115 (64%) |
125 (69.4%) |
45 (25.0%) | 77 (42.8%) | 55 (30.6%) | 8 (4.4%) | |||||
| Colchicine | 65 ± 14 | 124 (69%) | 121 (67.2%) | 39 (21.7%) | 92 (51.1%) | 51 (28.3%) | 4 (2.2%) | ||||||
| Imazio et al. (2014) | Placebo | 68.0 ± 10.0 | 115 (63.9%) | 122 (67.8%) | 42 (23.3%) | 59 (32.8%) | 69 (38.3%) | 11 (6.1%) | |||||
| Colchicine | 67.0 ± 11.1 | 133 (73.9%) | 121 (67.2%) | 38 (21.1%) | 63 (35.0%) | 62 (34.4%) | 11 (6.1%) | ||||||
| Inan et al. (2011) | Control | 47.8 ± 9.9 | 24 (54%) | 22 (50%) | 9 (20%) | 37 (84%) | 44 (100%) | ||||||
| Indomethacin | 50.3 ± 8.3 | 23 (56%) | 23 (56%) | 12 (29%) | 33 (80%) | 41(100%) | |||||||
| Meuring et al. (2015) | Placebo | 64.7 ± 10.6 | 88 (88.9%) | 27.6 ± 4.3 | 62 (62.6%) | 21 (21.2%) | 52 (52.5%) | 60 (60.7%) | 15 (15.2%) | 2.9 (3%) | 35 (35.4%) | 36 (36.4%) | 28 (28.3%) |
| Colchicine | 64.2 ± 11.8 | 82 (83.7%) | 26.7 ± 3.8 | 59 (60.2%) | 23 (23.5%) | 58 (59.2%) | 48 (48.9%) | 15 (15.3%) | 3.0(3%) | 27 (27.6%) | 43 (43.9%) | 28 (28.6%) |
Legend: VA valvular disease; PE pleural effusion